PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

NCT02401061 | Terminated Phase 1 DMC

• 1 other identifier: PRTX-100-202
• Study Type: interventional
• Target: 13
• Locations: 2 countries
• Sites: 11

Brief Summary

Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been shown to raise platelet counts in a mouse model of immune thrombocytopenia (ITP). The primary objective of the study is to assess the efficacy of PRTX-100 in terms of platelet response in patients with chronic/persistent ITP. Funding Source - FDA OOPD (1R01FD005750-01A1)

Conditions

Immune Thrombocytopenia

Keywords

ITP; Thrombocytopenia

Outcome Measures

Primary Outcomes (1)

• Platelet Response, Change from Baseline

  The primary efficacy endpoint is platelet response defined as a platelet count ≥ 30,000/μL and at least a doubling of baseline platelet count (determined on Day 1 prior to PRTX-100 administration) in patients with a baseline platelet count \< 30,000/μL. In patients receiving permitted treatments for ITP with a baseline platelet count ≥ 30,000/μL and \< 50,000/μL, an increase in platelet count to ≥ 50,000/μL and at least a doubling of baseline platelet count or an increase to \> 100,000/μL be considered a platelet response.

  Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337

Secondary Outcomes (5)

• Complete platelet response, Change from Baseline

  Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337

• Time to platelet response defined as the mean number of days from first PRTX-100 dose until platelet response

  Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337

• Durability of platelet response

  Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337

• Concomitant ITP medication use (frequency and amount)

  Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337

• Adverse Events

  Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337

Study Arms (1)

PRTX-100

EXPERIMENTAL

Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses \> 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.

Drug: PRTX-100

Interventions

PRTX-100 DRUG

Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.

Also known as: SpA, Staphylococcal Protein A

PRTX-100

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing and able to provide written informed consent prior to initiation of any study-related procedures
• Male or female ≥ 18 years of age
• ITP that has persisted for ≥ 3 months. ITP must be diagnosed in accordance The American Society of Hematology 2011 Evidence-based Practice Guideline for Immune Thrombocytopenia (Neunert et al. 2011) or the International Consensus Report on The Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as locally applicable.
• Received ≥ 1 typical regime for the treatment of ITP. Splenectomy is considered one standard ITP treatment
• A mean platelet count of \< 30,000/μL, with no individual platelet count \> 35,000/μL; or for those subjects receiving a constant dose of permitted treatments for ITP: a mean platelet count \< 50,000/μL, with no count greater than 55,000/μL. (Note: The mean platelet count must be determined based on 2 platelet counts including one obtained within ≤ 7 days of first PRTX-100 dose and the other within ≤ 30 days of the first dose of PRTX-100.)
• If on corticosteroids, a dose of \< 1 mg/kg prednisone per day or equivalent that has been stable for ≥ 21 days prior to the first dose of PRTX-100. High-dose pulse steroid therapy is NOT allowed within 14 days prior to the first dose of PRTX-100.
• If receiving eltrombopag or romiplostim, the dose must have been stable for ≥ 21 days prior to the first dose of PRTX-100
• If on steroid-sparing adjunctive immunosuppression with cyclosporine, azathioprine, mycophenolate, or 6-mercaptopurine, the dose must have been stable for ≥ 30 days prior to the first dose of PRTX-100 and must be expected to remain stable through study Day 29, unless dose reduction is required due to toxicities. Treatment with other cytotoxic agents (e.g. cyclophosphamide, vincristine) are not allowed within three months prior to the first dose of PRTX- 100.
• Any prior treatment with rituximab or any other anti-CD20 agent must have been \> 6 months prior to the first dose of PRTX-100
• If female, must not be pregnant (pregnancy testing will be performed locally in all female patients of childbearing potential), must not be nursing and must be one of the following:
• Surgically sterile (bilateral tubal ligation, hysterectomy)
• Postmenopausal with last natural menses \> 24 months prior
• Premenopausal and using an acceptable form of birth control. Acceptable forms of birth control include: hormonal contraceptives (implantable, oral, patch) used for ≥ 2 months prior to screening or double barrier methods (any combination of two of the following: intrauterine device \[IUD\], male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). All premenopausal females must have a negative urine or serum pregnancy test at screening and on Day 1 prior to first PRTX-100 treatment.

You may not qualify if:

• Splenectomy ≤ 90 days prior to the first dose of PRTX-100
• Unstable coronary artery disease or other medical condition (such as type 1 diabetes) that, in the Investigator's opinion, might increase the risk to the patient
• Evidence of active infection requiring antibiotic therapy ≤ 14 days prior to the first dose of PRTX- 100
• Myelodysplastic syndrome. If clinically significant anemia or pancytopenia exists, documentation of a bone marrow aspirate within 24 months prior to the first dose of PRTX-100 showing no evidence of myelodysplasia is required.
• Medical history of vasculitis or lupus erythematosus
• Propensity to allergic reactions defined as a history of allergic reaction to more than one medication
• History of any treatment for cancer within the past two years other than basal cell or squamous cell carcinoma of the skin that has been treated with curative intent
• Seropositive for human immunodeficiency virus (HIV)
• History of acute/chronic hepatitis B or C and/or carriers of hepatitis B or C (positive for hepatitis B surface antigen or positive anti-hepatitis C antibody test) and evidence of current or active infection (e.g. HCV RNA test)
• History suggestive of substance abuse
• History or evidence on physical examination or screening laboratory tests of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the study drug
• Treatment with IVIG ≤ 14 days prior to the first dose of PRTX-100
• Treatment with an anti-Rh D antigen agent (e.g. WinPho) ≤ 14 days prior to the first dose of PRTX-100
• Use of any investigational drug, other than eltrombopag or romiplostim, ≤ 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first dose of RTX-100
• Not willing to stay at the study site for 4 hours after each PRTX-100 infusion

Sponsors & Collaborators

• Protalex, Inc.: lead

Study Sites (11)

USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

Location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Michigan Center of Medical Research

Farmington Hills, Michigan, 48334, United States

Location

Weil-Cornell Medical College

New York, New York, 10065, United States

Location

Gabrail Cancer Center

Canton, Ohio, 44718, United States

Location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

Aberdeen Royal Infirmary

Aberdeen, AB, AB25 27N, United Kingdom

Location

Leicester Royal Infirmary

Leicester, Leichester, LE1 5WW, United Kingdom

Location

Queen Elizabeth Hospital

Birmingham, B15 2TH, United Kingdom

Location

Glasgow Royal Infirmary

Glasgow, G4 0SF, United Kingdom

Location

Norfolk and Norwich Hospital

Norwich, NR4 7UY, United Kingdom

Location

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia

Interventions

Staphylococcal Protein A

Condition Hierarchy (Ancestors)

Purpura, Thrombocytopenic; Purpura; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Thrombotic Microangiopathies; Blood Platelet Disorders; Cytopenia; Hemorrhagic Disorders; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Manifestations; Signs and Symptoms

Intervention Hierarchy (Ancestors)

Antigens, Bacterial; Bacterial Proteins; Proteins; Amino Acids, Peptides, and Proteins; Antigens; Biological Factors

Study Officials

• William E Gannon Jr., MD

  Protalex, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2015
• First Posted: March 27, 2015
• Study Start: September 1, 2015
• Primary Completion: March 1, 2019
• Study Completion: June 4, 2019
• Last Updated: July 5, 2019

Record last verified: 2019-07

Locations

GB (5); US (6)